The transcription factor RUNX2 fuels YAP1 signaling and gastric cancer tumorigenesis

Zhengjun Guo,Kai Zhou,Qiang Wang,Yusheng Huang,Jia Ji,Yuan Peng,Xiaoyue Zhang,Taihao Zheng,Zhen Zhang,Daochen Chong,Zhenzhou Yang

DOI: https://doi.org/10.1111/cas.15045

IF: 5.7

2021-07-16

Cancer Science

Abstract:<p>Despite considerable efforts in the detection and treatment of gastric cancer, the underlying mechanism of the progression of gastric cancer remains unknown. Our previous work has demonstrated the remarkable role of RUNX2 in fueling the invasion and metastasis of gastric cancer. The present study aimed to elucidate the role of RUNX2 in tumorigenesis of gastric cancer. We assessed Runx2 expression and its clinical significance via bioinformatic analysis of the TCGA and GEO databases. Roles for Runx2 in self-renewal and tumorigenesis were examined in vitro and in vivo. Further bioinformatic analysis was applied to study the mechanism of gastric cancer progression. We found that Runx2 was highly expressed in the early stage of gastric cancer and positively correlated with a poor clinical outcome of patients. Runx2 was also significantly correlated with clinicopathological features, such as Hp infection, new neoplastic events, primary therapeutic outcome, ethnicity, race and tumor stage. Multivariate analysis revealed that together with Runx2, age, cancer status, M stage and T stage were independent prognostic factors for the outcome of gastric cancer patients. RUNX2 overexpression induced increased anchorage-independent colony formation, sphere formation and tumorigenesis in gastric cancer cells in vitro and in vivo. Mechanistically, bioinformatic analysis indicated that YAP1 might be a downstream target of RUNX2. Specific knockdown of YAP1 reduced the tumor-initiating ability of gastric cancer cells induced by ectopic Runx2 expression. Our findings support the hypothesis that RUNX2 exerts oncogenic properties via YAP1 regulation, highlighting essential roles for RUNX2 and YAP1 in gastric carcinogenesis and suggesting potential therapeutic targets.</p>

oncology